Literature DB >> 9809973

Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles.

T L Plank1, R S Yeung, E P Henske.   

Abstract

Tuberous sclerosis is an inherited syndrome associated with mutations in two tumor suppressor genes: TSC1 and TSC2. Tuberin, the product of TSC2, appears to be localized to the Golgi apparatus and may have a function in vesicular transport. The function of hamartin, the product of TSC1, is not known. In this report, we demonstrate an interaction between hamartin and tuberin, which is detectable at endogenous protein levels. Hamartin is present in a cell line derived from the Eker rat that lacks functional tuberin, indicating that the stability of hamartin is not dependent on its interaction with tuberin. Hamartin is localized to the membrane/particulate (P100) fraction of cultured cells. The P100 localization is unchanged in the Eker cells. Finally, we show that at endogenous expression levels, hamartin has a punctate pattern of immunofluorescence in the cytoplasm. Taken together, the presence of hamartin in the membrane/particulate fraction and its pattern of cytoplasmic staining suggest that it is localized to cytoplasmic vesicles. If altered vesicular trafficking leads to tumorigenesis in tuberous sclerosis, TSC1 and TSC2 may have a novel mechanism of tumor suppression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9809973

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  61 in total

Review 1.  Signaling by target of rapamycin proteins in cell growth control.

Authors:  Ken Inoki; Hongjiao Ouyang; Yong Li; Kun-Liang Guan
Journal:  Microbiol Mol Biol Rev       Date:  2005-03       Impact factor: 11.056

Review 2.  Regulation of mTORC1 by PI3K signaling.

Authors:  Christian C Dibble; Lewis C Cantley
Journal:  Trends Cell Biol       Date:  2015-07-06       Impact factor: 20.808

3.  Analysis of TSC1 mutation spectrum in mucosal melanoma.

Authors:  Meng Ma; Jie Dai; Tianxiao Xu; Sifan Yu; Huan Yu; Huan Tang; Junya Yan; Xiaowen Wu; Jiayi Yu; Zhihong Chi; Lu Si; Chuanliang Cui; Xinan Sheng; Yan Kong; Jun Guo
Journal:  J Cancer Res Clin Oncol       Date:  2017-11-28       Impact factor: 4.553

4.  Lymphangioleiomyomatosis.

Authors:  Angelo M Taveira-DaSilva; Wendy K Steagall; Joel Moss
Journal:  Atlas Genet Cytogenet Oncol Haematol       Date:  2009

5.  The determinants of head and neck cancer: Unmasking the PI3K pathway mutations.

Authors:  Fernanda S Giudice; Cristiane H Squarize
Journal:  J Carcinog Mutagen       Date:  2013-08-02

6.  Cypermethrin Activates Autophagosome Formation Albeit Inhibits Autophagy Owing to Poor Lysosome Quality: Relevance to Parkinson's Disease.

Authors:  Abhishek Kumar Mishra; Saumya Mishra; Charul Rajput; Mohd Sami Ur Rasheed; Devendra Kumar Patel; Mahendra Pratap Singh
Journal:  Neurotox Res       Date:  2017-08-24       Impact factor: 3.911

7.  Faslodex inhibits estradiol-induced extracellular matrix dynamics and lung metastasis in a model of lymphangioleiomyomatosis.

Authors:  Chenggang Li; Xiaobo Zhou; Yang Sun; Erik Zhang; John D Mancini; Andrey Parkhitko; Tasha A Morrison; Edwin K Silverman; Elizabeth P Henske; Jane J Yu
Journal:  Am J Respir Cell Mol Biol       Date:  2013-07       Impact factor: 6.914

8.  Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR.

Authors:  Hongbing Zhang; Gregor Cicchetti; Hiroaki Onda; Henry B Koon; Kirsten Asrican; Natalia Bajraszewski; Francisca Vazquez; Christopher L Carpenter; David J Kwiatkowski
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

9.  Role of the Tsc1-Tsc2 complex in signaling and transport across the cell membrane in the fission yeast Schizosaccharomyces pombe.

Authors:  Sanae Matsumoto; Amitabha Bandyopadhyay; David J Kwiatkowski; Umadas Maitra; Tomohiro Matsumoto
Journal:  Genetics       Date:  2002-07       Impact factor: 4.562

Review 10.  Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer.

Authors:  Margaret A Knowles; Fiona M Platt; Rebecca L Ross; Carolyn D Hurst
Journal:  Cancer Metastasis Rev       Date:  2009-12       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.